KEYNOTE-B96
-
Pembrolizumab Plus Chemotherapy Improves Outcomes in Platinum-Resistant Ovarian Cancer
The KEYNOTE-B96 Phase 3 trial demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with KEYTRUDA plus chemotherapy with or without bevacizumab in platinum-resistant recurrent ovarian cancer. The study showed PFS benefits in the overall population and OS benefits in patients with PD-L1 expressing tumors. The FDA has granted priority review to Merck’s sBLA for this combination, with a PDUFA date of Feb. 20, 2026, potentially changing treatment for this challenging disease.
